Backgrounds: To understand the clinical impact of PD-1/L1 expression in thymoma (TM) and thymic carcinoma (TC), we evaluated the frequency of PD-1/L1 expression in pre/post chemotherapy specimens and the correlation with the treatment efficacy. Methods: The expression of PD-1/L1 was evaluated using immunohistochemistry in patients with TM or TC treated with chemotherapy between 2000 and 2014. Using formalin-fixed, paraffin-embedded tissue samples and a PD-L1 antibody, the expression of PD-L1 in the TM and TC specimens was reported in terms of the H-score (0-300), with a score ≥1 being defined as positive. The PD-1 expression in the tumorinfiltrating immune cells was evaluated based on the intensity (0-3) of staining using a PD-1 antibody. The objective response rate, progression-free survival, and the difference in PD-1/L1 expression between the pre/post chemotherapy were evaluated. Results: Thirty patients (TM/TC 12/18) were evaluated. PD-L1 positivity were TM/TC 67%/41%. Within the PD-L1 positive/negative populations, the objective response rates were 50%/0% for TM and 14%/20% for TC. No significant differences in progression-free survival were seen according to the PD-L1 expression status. Increases in both the PD-L1 and PD-1 scores were observed after chemotherapy in six serial pre/post chemotherapy TM specimens, with a mean PD-L1 score and a median PD-1 intensity of 42/93, and 0/2.5, respectively. Conclusions: The substantially high expression of PD-L1 and the increase in PD-L1 and PD-1 expression after chemotherapy supports anti-PD-1/L1 drugs therapy for TM and TC as well as the development of a strategy for its sequential use after chemotherapy.
Introduction
Thymic epithelial tumors (TETs) are rare neoplasms with an incidence rate of 0.17 per 100,000 person-years [1] . The classification developed by the World Health Organization (WHO) divided TETs according to an increasing degree of aggressiveness: thymomas (TMs; types A, AB, B1, B2, and B3), and thymic carcinomas (TCs; type C) in 2004. Patients with advanced TETs are candidates for chemotherapy. The rarity and heterogeneity among TET subtypes make it difficult to develop a standard treatment. Today, platinumbased regimens, especially carboplatin and paclitaxel, are widely used for TCs because of its promising efficacy and lower toxicity compared with anthracycline therapy [2] [3] [4] . Sunitinib has been the only molecular-targeted therapy which suggested efficacy for TCs [5] , while other biological agents have demonstrated a lack of activity against TETs [6] . Thus, there is a pressing need for the development of newer treatment modalities for TETs.
In recent years, immunotherapy involving drugs such as anti-programmed death 1 (PD-1) and its ligand (PD-L1) and anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) have changed conventional chemotherapies, with improved treatment effects observed for melanoma, renal cell cancer, lung cancer, and other cancers [7] [8] [9] [10] . Among the different tumor types, a response to anti-PD-1/L1 drugs has been associated with PD-L1 tumor expression, PD-L1 or PD-1 tumor infiltrating immune cell (TIIC) expression, and somatic mutations [11] [12] [13] [14] [15] . Moreover, clinical studies have suggested that the tumor expression of PD-L1 was related to an increase in the objective response rate (ORR) to anti-PD-1/L1 drugs [10, 14] . Previous studies using immunohistochemistry methods have demonstrated that PD-L1 is expressed in TETs [16, 17] . Thus, anti-PD-1/L1 drugs are candidates for the treatment of TETs.
PD-1 is an immune-checkpoint protein for immune tolerance that inhibits T cell activation by binding with PD-L1 and other ligands. PD-1 modulates positive selection in the thymus and is constitutively expressed on thymic T-lymphocytes and upregulated on activated T-cells, B-cells, myeloid cells [18] [19] [20] , and TIICs in many epithelial cancers. Once PD-L1 is expressed on tumor cells, the PD-1/L1 signaling pathway facilitates escape from antitumor immunity by maintaining an immunosuppressive tumor microenvironment.
To evaluate the possibility of using anti-PD-1/L1 drugs to treat patients with TETs, we evaluated the presence of PD-1/L1 expression in specimens obtained before and after chemotherapy and the correlation between PD-1/L1 expression before chemotherapy and the treatment efficacy of chemotherapy in TETs.
Materials and methods

Patients and samples
Consecutive patients with pathologically confirmed primary TM or TC who underwent chemotherapy between 2000 and 2014 at the National Cancer Center Hospital, Tokyo, Japan, were included. The relevant clinical data were collected by retrospective reviews of the patients' charts. The institutional review board approved the study (2010-0077). Pathological diagnosis was based on WHO classification on the 2004 (3rd) edition [21] .
Immunohistochemistry
Formalin-fixed, paraffin-embedded (FFPE) tissue specimens obtained from either biopsies or surgeries were examined. Each FFPE block obtained from a surgical specimen was selected from a centrally located area of the tumor that had been confirmed to contain tumor cells using hematoxylin and eosin staining.
FFPE blocks were sectioned at a thickness of 4 m and deparaffinized, then subjected to immunohistochemical staining using a previously described method [17] with a previously validated rabbit monoclonal PD-L1 antibody (E1L3N, 1:800, Cell Signaling Technology, Danvers, MA) and a PD-1 antibody (NAT105, 1:100, Abcam, Cambridge, UK). For visualization of the antigen, a peroxidase-labeled secondary antibody (EnVision/HRP system, DAKO, Carpinteria, CA) was applied. Furthermore, we used antihuman CD4 (4B12, Leica, Newcastle, UK) and anti-human CD8 (4B11, Leica, Newcastle, UK) to detect TIICs.
Before scoring, specimens without a sufficient amount of tumor cells were excluded. Our criterion for the minimum amount of tumor cells required for an evaluation was a half field of view in a high-power field (magnification ×400). Two independent observers (Y.K and K.T) examined the stained slides in a blinded fashion. Each of them evaluated the morphological features of the thymic epithelial cells and determined the epithelial marker expression immunohistologically when they experienced difficulty in distinguishing the epithelial components in TM, especially types B1 and B2. A semiquantitative approach (H-score) [22] was used to evaluate the tumor expression of PD-L1. The staining percentages (0%-100%) and the intensity of PD-L1 (0-3: 0, negative; 1, very weak; 2, moderate; and 3, strong) in tumor cells were evaluated for two representative parts, and the mean PD-L1 expression scores (0-300) were calculated by multiplying the percentage of the stained tumor area by the staining intensity. For the PD-L1 expression scores, 3 (1%) was used as the positive cutoff score. We used the term PD-L1 "positive" only for specimens before chemotherapy to evaluate the effects of chemotherapy and PD-L1 expression accurately. A representative staining result is shown in Fig. 1 . On the other hand, a qualitative approach (0-3: 0, negative; 1, very weak; 2, moderate; and 3, strong) was used for evaluating the expression of PD-1 on the most strongly stained area of the specimens because of the heterogeneity of the PD-1 staining pattern. A PD-1 score of 1-3 was evaluated as "positive" only for specimens obtained before chemotherapy.
Correlation between immunohistochemistry and chemotherapy response
The treatment effect of the first-line chemotherapy was assessed using the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1. The ORR for chemotherapy and overall survival (OS; from the day of the start of chemotherapy to the date of death from any cause or the date on which the patient was lost to follow up) were analyzed by stratifying the specimens according to their PD-1/L1 expression statuses. To evaluate the difference in PD-1/L1 expression before and after chemotherapy, TM specimens were evaluated. However, serial specimens of TCs were not obtained.
Statistical analyses
The PD-L1 score and the PD-1 score were evaluated as continuous variables, and the differences in these scores were analyzed using the Wilcoxon signed rank test.
To avoid effects other than those related to chemotherapy, patients who underwent surgery or radiation therapy after chemotherapy were excluded from the PFS analysis. The PFS was estimated according to the Kaplan-Meier method and was compared between the two groups using a log-rank test. A two-sided P value ≤ 0.05 was considered statistically significant. Statistical analyses were performed with Stata version 13.0 (College Station, Texas, USA).
Results
Patient characteristics
A total of 75 patients with TET underwent chemotherapy. As for TM, of the 17 patients who received chemotherapy, 18 specimens from 12 patients were available for analysis. As for TC, of the 58 patients who received chemotherapy, 18 specimens from 18 patients with TC were available for analysis (Fig. 2) . Three TM and four TC surgical specimens had been previously evaluated for PD-L1 expression in a tissue microarray analysis performed in our previous study [17] .
Thus, 36 specimens from 30 patients with TMs or TCs were analyzed. The patient characteristics are shown in Table 1 . Of the 30 patients, 12 had TM (B1 = 1, B2 = 7, B3 = 3, others = 1) and 18 had TC (squamous cell carcinoma = 12, neuroendocrine carcinoma = 2, adenocarcinoma = 1, others = 3). All the patients received chemotherapy including one platinum compound, and all chemotherapy regimens for TM were CODE (cisplatin + vincristine + doxorubicin + etoposide). Among five patients relapsed after surgery, no rebiopsies were carried out. We evaluated specimens from surgeries. Each specimen's status (either from biopsy or from surgery, and either before or after chemotherapy), PD-L1 score, PD-L1 positivity, and PD-1 intensity and the treatment effect of chemotherapy are shown in Table 2 . In the analysis examining the efficacy of chemotherapy, 9 TM specimens and 17 TC specimens were analyzed. Among patients with TM, two patients had pure red cell aplasia, one had myoasthenia gravis, and one had myopathy other than myoasthenia gravis.
Tumor expression of PD-L1 in TMs and TCs
PD-L1 was detectable in the tumor epithelial cells, while TIICs did not stain positive for PD-L1. The mean (range) of the PD-L1 scores was 51 (0-140) for the TMs and 40 (0-180) for the TCs. The median score was 30 for the TMs and 0 for the TCs; 67% of the TMs and 41% of the TCs were positive for PD-L1 (Table 2) .
There was no significant relationship in PD-L1 score and smoking status (P = 0.648). Except for three patients with unknown smoking status, the mean (range) of the PD-L1 scores was 49 (0-230) and PD-L1 was positive in 50% of past and current smokers, while the mean (range) of the PD-L1 scores was 36 (0-150) and PD-L1 was positive in 56% of never smokers.
As for the historical subtype of TC, the PD-L1 scores of two patients with neuroendocrine carcinoma and one patient with adenocarcinoma were all 0. The mean (range) of the PD-L1 scores was 47 (0-180) and 58% was PD-L1 positive for 12 patients with squamous cell carcinoma.
Comparing specimens' status in TC, 75% (3/4) of surgery specimens was PD-L1 positive with the mean (range) score of 98 (0-180), Stage = Masaoka Koga Stage, Sq = squamous cell carcinoma, NEC = neuroendocrine carcinoma, Ad = adenocarcinoma, CODE = cisplatin + vincristine + doxorubicin + etoposide, CBDCA = carboplatin, PTX = paclitaxel, GEM = gemcitabine, CDDP = cisplatin, ETP = etoposide. NOS = thymoma/thymic carcinoma not otherwise specified, Sq = squamous cell carcinoma, NEC = neuro endocrine carcinoma, PR = partial response, SD = stable disease, PD = progressive disease, PRCA = pure red cell aplasia, MG = myoasthenia gravis.
while 31% (4/13) of biopsy specimens was PD-L1 positive with the mean (range) score of 22 (0-150).
Associations between PD-L1 expression and treatment effect
The ORRs for the TMs and TCs were 33% and 18%, and the disease control rates (DCRs) were 100% and 76%, respectively. The ORR was higher in the PD-L1 positive group (50% vs 0%) among the TMs, but a similar trend was not observed among the TCs.
The median OS of the PD-L1 positive and negative groups among the patients with TMs were 77.1 months (95% CI, 41.7 months-NA [not achieved]) and 58.5 months (95% CI, 34.5 months-NA), respectively. No significant differences were observed when analyzed according to the PD-L1 expression status (P = 0.624). The median OS of the PD-1 positive and negative groups among the patients with TMs were 71.5 months (95% CI, 41.7 months-NA) and 78.1 months (95% CI, 34.5 months-NA), respectively. No significant differences were observed when analyzed according to the PD-L1 expression status (P = 0.689).
The median OS of the PD-L1 positive and negative groups among the patients with TCs were 27.3 months (95% CI, 9.5 months-NA) and 47.7 months (95% CI, 2.1-69.1 months), respectively. Again, no significant differences were observed when analyzed according to the PD-1 expression status (P = 0.449). The median OS of the Table 3 Efficacy of chemotherapy in the PD-1/L1 positive and negative groups in thymomas and thymic carcinomas.
PD-L1
PD-1 PD-1 positive and negative groups among the patients with TCs were 30.9 months (95% CI, 9.5 months-NA) and 47.6 months (95% CI, 2.1-69.1 months), respectively. No significant differences were observed when analyzed according to the PD-L1 expression status (P = 0.650) ( Table 3 ).
Tumor expression of PD-1 on TIICs
PD-1 was detectable in TIICs (scored) and other immune cells, such as in the stroma (not scored). The median (range) of the PD-1 scores was 0 (0-3) for the TMs and 0 (0-3) for the TCs; 44% (4/9) of the TMs and 47% (8/17) of the TCs were positive.
Expression of PD-L1 on tumor cells and PD-1 on TIICs before and after chemotherapy
Among the specimens obtained after chemotherapy, all (9/9) of the TMs and (1/1) TC expressed both PD-L1 in the tumor cells and PD-1 in the TIICs. Six patients with TM had serial specimens obtained both before and after chemotherapy. When the PD-L1 scores from before and after chemotherapy were compared, the mean PD-L1 score increased from 42 (range 0-130) to 93 (range 25-180) after chemotherapy (P = 0.073). PD-L1 expression positivity increased from 67% to 100% in the same sample set. The PD-1 scores (range) for the TIICs increased from 0 (0-3) to 2.5 (2-3) after chemotherapy (P = 0.070). PD-1 positivity increased from 33% to 100% in the same sample set (Table 4 ).
Discussion
Here, we demonstrated that 67% of TMs and 41% of TCs were positive for PD-L1 expression as determined using a validated antibody (clone E1L3N) and specimens obtained before chemotherapy. In six serial TM specimens, both the tumor expression of PD-L1 and the TIIC expression of PD-1 increased to 100% after chemotherapy. To our knowledge, this is the first report regarding the positivity of PD-L1 and PD-1 in TETs using serial tissue samples obtained before and after chemotherapy.
The substantially high expression rate of PD-L1 in TETs was similar to the results of a previous study [17] . The frequency of PD-L1 expression as determined using the antibody clone E1L3 N in other tumors was as follows: 15%-22% in non-small cell lung cancer [23] , 0% in small cell lung cancer [24] , and 20% in malignant pleural mesothelioma [25] . Compared with these, the positivity of PD-L1 expression in TETs was relatively high and could have important clinical implications for anti-PD-1/L1 drug treatment. In detail, the frequency of PD-L1 expression in TETs differed from that observed in our previous study (23% [23/101] in TMs and 70% [25/38] in TCs) [17] . The proportion of histological subtypes in TM might have some influence on the heterogeneity of the PD-L1 frequency. No WHO histological type A or AB specimens were included in this study, and the PD-L1 scores of types A and AB were relatively lower than those of types B1-3 in previous studies [16, 17] . Specimens in more advanced stages with higher PD-L1 expression levels [17] may also explain the difference in the PD-L1 frequency of the specimens examined in these two studies.
From our study, PD-L1 expression was an inconclusive biomarker as a predictive and prognostic factor of chemotherapy, respectively. The absence of a consistent trend between the tumor expression of PD-L1 and ORR does not suggest the usage of PD-L1 expression as a predictive marker. In published articles, a study on melanoma has shown that the ORR of dacarbazine or paclitaxel combined with carboplatin was relatively low in a PD-L1 positive group (9.1% vs 13.0%) [12] , though a study on triple-negative and HER-2 positive breast cancer has shown that the expression of PD-L1 on TIICs was positively correlated with a response to anthracycline plus taxane with carboplatin combination therapy [26] . Our previous study analyzing a larger number of subjects also showed that PD-L1 expression was not a prognostic factor [17] . A high level of tumor PD-L1 expression has been associated with a poor prognosis in non-small cell lung cancer [27] , renal cell carcinoma [28] , bladder cancer [29] , and gastric cancer [30] , while it was associated with a better prognosis in malignant melanoma [12] . In cervical cancer [31] and breast cancer [15] , the expressions of PD-1 and PD-L1 on TIICs also played an important role in the effect of chemotherapy.
The six serial TM specimens obtained before and after chemotherapy demonstrated that the tumor expression of PD-L1 and the TIIC expression of PD-1 increased after chemotherapy. Based on some studies, our results can be explained by the "immunogenic cell death" of tumor cells after chemotherapy. Previous in vivo studies have shown an increase in PD-L1 expression after chemotherapy or radiation therapy by enhancing the activation of CD8 T cells [32] . Furthermore, doxorubicin and paclitaxel, which we used in our series, are known to induce immunogenic cell death [33] . Unlike apoptosis, the immunogenic cell death of tumor cells enhances the activation of dendritic cells, sequentially activating T-cells to produce IFN-␥, which induces the expression of PD-L1 on the tumor cells [34] .
Our study had several limitations. First, the PD-L1 positivity in the surgical specimens was higher than that for the biopsy specimens for TCs, and the difference in specimens might be a confounding factor when comparing the six serial biopsies in the TM group. As a feature of our PD-L1 scoring method (H-score), as long as the specimens contained a sufficient amount of tumor cells, they were regarded as being eligible for evaluation. Not a few specimens from biopsies were excluded for validation because of this reason. However, a notable number of biopsy specimens had scores as high as those of the surgical specimens, as shown in Table 2 . As a feature of our PD-L1 scoring method (H-score), as long as the specimens contained a sufficient amount of tumor cells, they were regarded as being eligible for evaluation. In non-small cell lung cancer, Kita- zono et al. showed that even small samples from a needle biopsy are adequate for evaluating PD-L1 expression in paired specimens (concordance, 92.4%) [35] . Specimens obtained through noninvasive procedures and enabling a precise pathological diagnosis are needed even more in this era of biomarker-driven therapy. Second, the number of patients who could be evaluated was limited. Considering the rarity of TETs, however, this study deserves to be reported as an initial study evaluating the relationship between PD-1/L1 expression and chemotherapy. Of note, the experience in patients with a history of autoimmune diseases is relatively limited, although patients with autoimmune diseases were able to be treated relatively safely with the anti-CTLA-4 ipilimumab on some case reports. However, the pathophysiology of dysimmune toxicities caused by anti-PD-1/L1 drugs therapy is still not well understood. Treatment decision for patients with TM, who have expected risks of autoimmune diseases, should be carefully carried out [36] .
Taken together, the present results confirm the relatively high proportion of PD-L1 expression in TET specimens among solid tumors, and the expression of PD-L1 in tumor cells and of PD-1 in TIICs after chemotherapy changed dynamically in a subset of patients with TM. These observations raise some practical considerations for the development of anti-PD-1/L1 drugs therapy. The increase in both PD-L1 and PD-1 expressions after chemotherapy also suggests the potential of new treatment combination strategies, such as anti-PD-1/L1 drugs therapy after chemotherapy for TETs.
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